trending Market Intelligence /marketintelligence/en/news-insights/trending/75q3cikf25kuiz3yp8kjiw2 content esgSubNav
In This List

Intec Pharma appoints director

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


Intec Pharma appoints director

Intec Pharma Ltd. appointed Roger Pomerantz as a director.

Pomerantz's appointment brings the number of Intec's board members to seven, six of whom are independent. Pomerantz is the president, CEO and board chairman of Seres Therapeutics Inc.

Jerusalem, Israel-based Intec Pharma is a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology. The Accordion Pill is an oral drug delivery system designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism.